U
IART icon

UBS’s Integra LifeSciences IART Stock Holding History

UBS’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-489
Closed -$9K – 10595
2014
Q1 		$9K Buy
+489
New +$9.44K ﹤0.01% 9007

Other funds holding IART

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS's IART Position: Q3 2014 in Review

UBS reduced its Integra LifeSciences (IART) stake by 25% in Q3 2014, selling an estimated $71.3K and leaving 10,850 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #5093.

UBS first reported a position in IART in Q2 2013 and has held it in 6 quarters since. The position peaked at $317K in Q2 2013. 143 funds tracked by Wall St. Rank hold IART as of Q3 2014.

  • UBS held 10,850 shares of Integra LifeSciences worth $220K as of Q3 2014.
  • UBS sold 3,584 Integra LifeSciences shares in Q3 2014, an estimated $71.3K.
  • Integra LifeSciences made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5093 holding.
  • UBS first reported a position in Integra LifeSciences in Q2 2013 and has held it in 6 quarters since.
  • UBS's Integra LifeSciences position peaked at $317K in Q2 2013.
  • 143 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.